Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.50 |
| ▸ | VNN1 | O95497 | 5/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13119258 | 0.92 | GSK3B (0.62) | GSK3BCDK2CCNE1 | |
| SCHEMBL14307158 | 0.89 | GSK3B (0.50) | GSK3BVNN1CHEK1CDK2CCNE1 | |
| SCHEMBL12953930 | 0.89 | GSK3B (0.51) | GSK3BVNN1CHEK1CDK2CCNE1 | |
| SCHEMBL14043163 | 0.88 | GSK3B (0.51) | GSK3BVNN1CHEK1CDK2CCNE1 | |
| SCHEMBL14545254 | 0.87 | GSK3B (0.51) | GSK3BVNN1CHEK1CDK2CCNE1 | |
| SCHEMBL14301571 | 0.87 | GSK3B (0.53) | GSK3BVNN1CHEK1CDK2CCNE1 | |
| SCHEMBL14301230 | 0.87 | GSK3B (0.53) | GSK3BVNN1CHEK1KDM4ECDK2 | |
| SCHEMBL13119260 | 0.86 | GSK3B (0.64) | GSK3BCDK2CCNE1 | |
| SCHEMBL14043165 | 0.85 | GSK3B (0.56) | GSK3BVNN1CHEK1KDM4ECDK2 | |
| SCHEMBL13289055 | 0.85 | GSK3B (0.51) | GSK3BVNN1CHEK1CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885VNN1 3825/4885PARP14 779/4885 |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885VNN1 3825/4885PARP14 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.